Get the Stockscreener App
2.86
3.25%
0.09
Pre-market:
2.83
-0.03
-1.05%
Fortress Biotech Inc stock is traded at $2.86, with a volume of 463.74K.
It is up +3.25% in the last 24 hours and up +18.67% over the past month.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
See More
Previous Close:
$2.77
Open:
$2.8
24h Volume:
463.74K
Relative Volume:
1.10
Market Cap:
$95.01M
Revenue:
$66.16M
Net Income/Loss:
$128.94M
P/E Ratio:
0.8987
EPS:
3.1823
Net Cash Flow:
$152.08M
1W Performance:
+0.35%
1M Performance:
+18.67%
6M Performance:
-13.86%
1Y Performance:
+54.59%
1-Day Range:
$2.80
$2.945
1-Week Range:
$2.72
$2.99
52-Week Range:
$1.70
$4.53
Fortress Biotech Inc Stock (FBIO) Company Profile
Name
Fortress Biotech Inc
Sector
Industry
Phone
781-652-4500
Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
2.86 | 95.01M | 66.16M | 128.94M | 152.08M | 3.1823 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-15-24 | Resumed | ROTH MKM | Buy |
| Aug-04-22 | Initiated | Ladenburg Thalmann | Buy |
| Oct-02-20 | Initiated | The Benchmark Company | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Feb-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
| Mar-22-17 | Initiated | JMP Securities | Mkt Outperform |
| Oct-03-16 | Initiated | ROTH Capital | Buy |
View All
Fortress Biotech Inc Stock (FBIO) Latest News
(FBIOP) Volatility Zones as Tactical Triggers - Stock Traders Daily
FBIOP Q4 2025 Earnings: Preferred Stock Reports Wider-than-Expected Loss Amid Narrowing Pipeline Progress - newsline.com
Fortress Biotech Preferred Stock (FBIOP) Edges Higher Before Resistance TestPut Support - newsline.com
FBIOP Q4 2025 Earnings: Preferred Stock Faces EPS Miss as Company Reports LossEPS Revision Trend - newsline.com
Fortress Biotech Preferred Stock (FBIOP) Faces Resistance, Slides 2.3% in Quiet SessionProtective Put - newsline.com
Fortress Biotech Preferred Stock (FBIOP) Pulls Back 2.3% as Shares Approach Key SupportDescending Triangle - newsline.com
Price-Driven Insight from (FBIOP) for Rule-Based Strategy - Stock Traders Daily
Fortress Biotech Inc stock (US32015L1035): Nasdaq-listed biotech moves in low-volume trade ahead of - AD HOC NEWS
Fortress Biotech Preferred Stock (FBIOP) Surges 5.19%, Nears Key Resistance at $21.5BPI Bear Confirmed - newsline.com
Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends? (FBIO) - Seeking Alpha
FBIO Q4 2025 Earnings: EPS Misses Estimates, Stock Moves HigherEarnings Quality Analysis - newsline.com
FBIO Q4 2025 Earnings: EPS Misses Estimates as Revenue Remains AbsentEarnings Seasonality - The Legal Advocate
Fortress Biotech Preferred (FBIOP) Rises 2.37%; Support and Resistance in FocusSynthetic Long - The Legal Advocate
Earnings call transcript: Journey Medical Q1 2026 shows 21% revenue rise By Investing.com - Investing.com South Africa
Earnings call transcript: Journey Medical Q1 2026 shows 21% revenue rise - Investing.com Canada
FBIOP Q4 2025 Earnings: Preferred Stock Reports Negative EPS Surprise Amid No Revenue Disclosure - newsline.com
Fortress Biotech Preferred Shares (FBIOP) Advance 2.45% as Support Holds Near $16Dark Pool Prints - The Legal Advocate
FBIO Q4 2025 Earnings: Deep EPS Miss Highlights Challenges for Pre-Revenue BiotechTrough Earnings Signal - Newser
(FBIOP) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Fortress Biotech Preferred Stock (FBIOP) Q4 2025 Earnings: EPS Misses Estimates by Over 108%Community Sell Signals - Newser
Fortress Biotech (FBIO) Gains 1.62% as Shares Approach Key Resistance at $2.97Stock Analysis - Newser
Fortress Biotech Inc. (FBIO) Moves Higher as Buyers Defend Key Support LevelLarge Cap Trends - The Legal Advocate
FBIO Q4 2025 Earnings: Significant EPS Surprise Miss Amid Limited Revenue DisclosureOne-Time Loss Impact - newsline.com
Fortress Biotech (FBIO) Q4 2025 Results Miss Estimates — EPS $-0.01 vs $0.11Consensus Beat Rate - Newser
FBIOP Stock Price, Quote & Chart | FORTRESS BIOTECH INCFBIO 9 3/8 PERP (NASDAQ:FBIOP) - ChartMill
Fortress Biotech (FBIO) Q4 2025 Earnings: Miss Sparks ConcernGAAP Earnings Report - Newser
Fortress Biotech (FBIO) Q4 2025 Miss: What Went WrongInterim Report - Newser
Journey Medical CEO to join online talk at A.G.P. health event - Stock Titan
Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference - Sahm
A. G. P. Maintains Fortress Biotech(FBIO.US) With Buy Rating, Raises Target Price to $5 - Moomoo
Why Fortress Biotech (FBIO) Just Surged +5.81% — Key Levels Ahead 2026-05-18Factor Timing - Newser
FBIO Stock Surges 12% Pre-Market After It Wins FDA Approval For Rare Pediatric Menkes Disease - Stocktwits
Number of shareholders of Fortress Biotech, Inc. – NASDAQ:FBIO - TradingView
Fortress Biotech, Inc.9.375% Series A Cumulative Redeemable Perpetual Preferred Stock - TradingView
Fortress Biotech stock (US32015L1035): FDA setback hits Menkes drug while investors eye next catalys - AD HOC NEWS
Fortress Biotech Inc at Planet MicroCap Showcase Virtual Investor Conference 2020 Transcript - GuruFocus
Highbridge (FBIO) reports 2.73M warrant-backed shares, 7.8% stake - Stock Titan
FBIOP | Fortress Biotech, Inc. 9.375% Insider Trading - Quiver Quantitative
Fortress Biotech (FBIO) Q1: EPS $2.82 Beats Est. -$0.22; Revenue - GuruFocus
Fortress Biotech Q1 2026 Earnings Call Transcript - MarketBeat
Fortress Biotech: Q1 Earnings Snapshot - marketscreener.com
Fortress Biotech, Inc. 1Q 2026: Revenue $15.92M, Net income $110.37M, EPS $2.82— 10-Q Summary - TradingView
Fortress Biotech posts $108.4M net income in Q1 2026, revenue $16.0M - TradingView
Priority review voucher sale drives Fortress Biotech (FBIO) Q1 2026 profit and cash surge - Stock Titan
Fortress Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Fortress Biotech (NASDAQ: FBIO) turns Q1 2026 profit after $205M PRV sale - Stock Titan
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewswire
Fortress Biotech stock (US32015L1035): Q1 earnings miss on revenue, but EMROSI shows momentum - AD HOC NEWS
FBIO: Q1 2026 revenue rose 21% to $16M, driven by EMROSI growth and expanding market access - TradingView
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - marketscreener.com
(FBIOP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Fortress Biotech Inc Stock (FBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):